Market Overview:
Report Attribute | Details |
|---|---|
| Base Year | 2023 |
| Forecast Years | 2024-2034 |
| Historical Years | 2018-2023 |
Market Size in 2023 | US$ 1.9 Billion |
Market Forecast in 2034 | US$ 75.1 Billion |
Market Growth Rate 2024-2034 | 39.93% |
How big is the AAV market?
The adeno-associated virus gene therapy market size reached a value of US$ 1.9 Billion in 2023 and expected to reach US$ 75.1 Billion by 2034, exhibiting a growth rate (CAGR) of 39.93% during 2024-2034.
The report offers a comprehensive analysis of the adeno-associated virus gene therapy market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the adeno-associated virus gene therapy market.
Request for a Sample Copy of this Report: https://www.imarcgroup.com/adeno-associated-virus-gene-therapy-market/requestsample
Adeno-associated Virus Gene Therapy Market Trends:
Adeno-associated virus (AAV) gene therapy refers to a type of gene therapy that uses adeno-associated viruses to deliver genetic material to cells in the body. The adeno-associated virus gene therapy market has witnessed exponential growth, propelled by several key market drivers. Firstly, the increasing prevalence of genetic disorders has heightened the demand for advanced therapeutic interventions. Consequently, pharmaceutical companies and biotech firms are heavily investing in adeno-associated virus gene therapy-based gene therapies to address unmet medical needs. Moreover, the FDA's increasing support and accelerated approval pathways for gene therapy products have fostered a conducive regulatory environment, encouraging innovation and market expansion.
Furthermore, the evolving landscape of personalized medicine has played an important role in the growth of the adeno-associated virus gene therapy market. The ability of adeno-associated virus gene therapy vectors to deliver genes to target cells with precision aligns perfectly with the personalized treatment approach, making them a promising avenue for treating a wide array of diseases. Additionally, the escalating research and development activities in the field of gene therapy, coupled with advancements in genetic engineering techniques, have significantly enhanced the efficiency and safety profile of adeno-associated virus gene therapy-based therapies. Collaborations and partnerships between pharmaceutical companies, research institutions, and academic centers have also propelled market growth. These collaborations facilitate the pooling of expertise, resources, and technologies, expediting the development and commercialization of adeno-associated virus gene therapies.
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adeno-associated virus gene therapy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adeno-associated virus gene therapy market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current adeno-associated virus gene therapy marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Competitive Landscape With Key Players:
The competitive landscape of the adeno-associated virus gene therapy market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Players:
- Novartis
- uniQure
- Shanghai Belief-Delivery BioMed Co., Ltd
- BioMarin Pharmaceutical
- Rocket Pharmaceuticals Inc.
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6765&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
